The JN1 variant harbors Leu455Ser and three mutations in non-spike proteins contributing to increased transmissibility and immune escape ability, also pseudovirus assay showed that the infectivity of JN.1 was significantly higher than its predecessor (1). JN.1 is about 3 to 5 times less susceptible to neutralizing antibodies than the XBB.1.5 variant that is in the updated booster raising concerns about its potential impact on public health (2) Recent data indicates a significant rise in cases associated with this variant, underscoring the need for immediate action. The antiviral Paxlovid, Remdesivir, and Molnupiravir continue to show activity against XBB-derived and BA.2.86 variants, suggesting that the current therapeutic tools remain effective(3).